150
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

DEVELOPMENT AND VALIDATION OF A STABILITY INDICATING UPLC METHOD, IDENTIFICATION, AND CHARACTERIZATION OF THREE DEGRADANT IMPURITIES IN PHARMACEUTICAL DOSAGE FORM OF RABEPRAZOLE SODIUM

, , , , &
Pages 2261-2278 | Published online: 18 Jun 2013
 

Abstract

A simple, sensitive, and reproducible ultra performance liquid chromatography (UPLC) coupled with a photodiode array detector method was developed for the quantitative determination of Rabeprazole Sodium and its three potential degradant impurities along with other six impurities in pharmaceutical dosage forms. Three unknown impurities of Rabeprazole, a proton pump inhibitor, were formed in the formulated drug under the stress conditions, [40°C/75% Relative humidity (RH) for 6 months] with relative retention times (RRT's) 0.10, 0.18, and 0.31. A thorough study was undertaken to characterize these potential degradants. These impurities were enriched by using various stressed conditions, isolated using preparative HPLC and characterized by NMR and MS. On the basis of the spectral data, the Impurity-I, II, and III were characterized as 2-Amino-1H-benzimidazole, 1H-Benzimidazol-2-ol, and 2-Benzimidazolethiol. Chromatographic separation was achieved on Acquity UPLC, RP18 column (100 × 2.1 mm i.d., 1.7 µm particle size). The instrument was set at a flow rate of 0.4 mL/min, the column oven temperature was maintained at 25°C, and the eluted compounds were monitored at 280 nm. The resolution between Rabeprazole and its nine impurities was greater than 1.5. Method was validated as per ICH guidelines.

Notes

##This column gives the 1H-1H multiplicity, s-singlet, dd-doublet of doublet, br-broad, m-multiplet.

##This column gives the 1H-1H multiplicity, s-singlet, br-broad.

##This column gives the 1H-1H multiplicity, m-multiplet, br-broad.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.